To study dose of aspirin effective in prevention of hypertensive disorders of pregnancy
Not Applicable
Completed
- Conditions
- Health Condition 1: O369- Maternal care for fetal problem, unspecified
- Registration Number
- CTRI/2018/01/011155
- Lead Sponsor
- Intramural grant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
1.History :
chronic hypertension /past history of severe PE/ past history of Eclampsia/ past history of severe intrauterine growth retardation with normal fetal morphology
2. Mean arterial pressure of more than 90th centile
3.Uterine artery raised pulsatality index of more than 90th centile
Exclusion Criteria
Maternal history:
1. Known case of Antiphospholipid antibody syndrome ,Thrombophillia.
2.Maternal medical diseases: peptic ulcer disease, bleeding disorder, chronic kidney disease.
Present pregnancy:
1. Maternal thrombocytopenia
( platelet count < 1.5 lac )
2. History of bleeding per vaginum
3. Fetus diagnosed with malformations/ anomaly/ aneuploidy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess differences in outcome between prophylactic uses of low-dose 150 mg aspirin versus 75 mg aspirin versus placebo. <br/ ><br>Timepoint: 22 weeks <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1. To document effect of different doses of aspirin on maternal (Incidence of early PE with delivery 34 weeks, placental abruption, eclampsia) and fetal (intrauterine growth retardation and stillbirth) outcomes <br/ ><br>2. To assess the correlation of various predictors(inclusion criteria) of PE with fetomaternal outcomes. <br/ ><br>Timepoint: 1 year